



Order

Order ref 6427

Order details on Saturday 06 March 2021

EVAg Products	Provider Lab	Unit price	Quantity	Estimated SubTotal
SARS-CoV-2 virus, strain hCoV-19/Netherlands/NoordHolland_10159/2021, South African variant, nextstrain clade 20H, lineage B.1.351 (014V-04058)	RIVM			
SARS-CoV-2 virus, strain hCoV-19/Netherlands/NoordHolland_10915/2021, Brazilian variant P1, nextstrain clade 20J, lineage B.1.1.28 P1 (014V-04089)	RIVM		5.1.1c	
SARS-CoV-2 virus, strain hCoV-19/Netherlands/NoordBrabant_10706/2021, Brazilian variant P2, nextstrain clade 20B, lineage B.1.1.28 P2 (014V-04090)	RIVM			
SARS-CoV-2 virus, strain hCoV-19/Netherlands/NoordHolland_20432/2020, VOC 202012/01, nextstrain clade 20B, lineage B.1.1.7 (014V-04031)	RIVM			
Order total				5.1.1c

Order status: Pending

Billing information:
 5.1.2e
 N.F.Gamaleya NRCEM
 Gamaleya str., 16
 Moscow
 Moskva
 123098
 Russia
 Telephone number:
 5.1.2e

Shipping information:
 5.1.2e
 N.F.Gamaleya NRCEM
 Gamaleya str., 16
 Moscow
 Moskva
 123098
 Russia
 Telephone number:
 5.1.2e

User-Project Objectives:

NRCEM N.F. Gamaleya, as a developer of the "Sputnik V" vaccine, is highly interested in assessing the neutralization activity of vaccine-induced antibodies against novel SARS-CoV-2 strains, including those belonging to the UK, South African, and Brazil lineages. Due to the fact that the representatives of some of those lineages still haven't been isolated in Russia, it is necessary to obtain those viruses in order to examine the efficacy of the vaccines against them.

Do you have the containment facilities and end-user qualification to handle the product(s) of interest?:

Yes

Intended use:

- Vaccine development
- Genomics and evolution
- Recombinant viral protein expression and purification

Ask for free of charge access:

No

I agree to the Terms and Conditions of Supply of Products and accept the Pricing Policy of the EVA Portal:

Agree